Skip to main content

Biotech Rebound Could Finally Be Afoot

A long-awaited biotechnology equity rebound could be materializing and some analysts believe it could have the momentum to carry into the end of 2022. Among the related exchange traded funds, the VanEck Vectors Biotech ETF (BBH), which is one of the bellwethers in this category, is higher by almost 14% since the start of the [...] The post Biotech Rebound Could Finally Be Afoot appeared first on ETF Trends .
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.